Purified T Cell Transplant Lowers Risk of Immune Reaction in Blood Cancer Patients

An experimental T cell therapy significantly reduced the risk of a debilitating immune reaction called chronic graft versus host disease in patients with several types of blood cancer. It’s one of the first examples of successfully engineering bone marrow grafts with a good outcome, explained David Porter, MD, director of Cell Therapy and Transplantation at the Abramson Cancer Center, who was not involved in the study.